Bioniche Pharma Launches Fomepizole Injection

Bioniche Pharma and Synerx Pharma, have launch of Fomepizole Injection, which is the generic equivalent of Paladin Labs’ Antizol.

George Zorich, president for US Operations at Bioniche Pharma, said: “The addition of Fomepizole to Bioniche’s product offering further broadens our base of niche injectables.”

Reportedly, Bioniche Pharma and Synerx Pharma entered into a definitive agreement, under which Bioniche Pharma has the rights to market and distribute Fomepizole in the US.

Bioniche will supply Fomepizole Injection in 1.5g /1.5ml vials.

Bioniche Pharma is a manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology and dermatology.